Factor Xa (Human, Highly Pure)

Description

Factor Xa (Human, Highly Pure)
Catalog number: B2010471
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 10 U
Molecular Weight or Concentration: na
Supplied as: Lyophilized Powder
Appearance: Powder
Applications: highly pure (specific activity ≥170 units/mg protein) Factor Xa from human plasma.
Storage: -20°C
Keywords: Coagulation Factor Xa, Human Plasma
Grade: Biotechnology grade. All solid components are highly pure (minimum 95%). All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Siegal DM, Curnutte JT, Connolly SJ, Lu G, Conley PB, Wiens BL, Mathur VS,
Castillo J, Bronson MD, Leeds JM, Mar FA, Gold A, Crowther MA. Andexanet Alfa
for the Reversal of Factor Xa Inhibitor Activity. N Engl J Med. 2015 Dec
17;373(25):2413-24.

2: Piran S, Khatib R, Schulman S, Majeed A, Holbrook A, Witt DM, Wiercioch W,
Schünemann HJ, Nieuwlaat R. Management of direct factor Xa inhibitor-related
major bleeding with prothrombin complex concentrate: a meta-analysis. Blood Adv.
2019 Jan 22;3(2):158-167.

3: Connolly SJ, Crowther M, Eikelboom JW, Gibson CM, Curnutte JT, Lawrence JH,
Yue P, Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen
AT, Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Demchuk AM, Pallin DJ,
Concha M, Goodman S, Leeds J, Souza S, Siegal DM, Zotova E, Meeks B, Ahmad S,
Nakamya J, Milling TJ Jr; ANNEXA-4 Investigators. Full Study Report of Andexanet
Alfa for Bleeding Associated with Factor Xa Inhibitors. N Engl J Med. 2019 Apr
4;380(14):1326-1335.

4: Samama MM. The mechanism of action of rivaroxaban–an oral, direct Factor Xa
inhibitor–compared with other anticoagulants. Thromb Res. 2011
Jun;127(6):497-504.

5: Frontera JA, Bhatt P, Lalchan R, Yaghi S, Ahuja T, Papadopoulos J, Joset D.
Cost comparison of andexanet versus prothrombin complex concentrates for direct
factor Xa inhibitor reversal after hemorrhage. J Thromb Thrombolysis. 2020
Jan;49(1):121-131.

6: Connolly SJ, Milling TJ Jr, Eikelboom JW, Gibson CM, Curnutte JT, Gold A,
Bronson MD, Lu G, Conley PB, Verhamme P, Schmidt J, Middeldorp S, Cohen AT,
Beyer-Westendorf J, Albaladejo P, Lopez-Sendon J, Goodman S, Leeds J, Wiens BL,
Siegal DM, Zotova E, Meeks B, Nakamya J, Lim WT, Crowther M; ANNEXA-4
Investigators. Andexanet Alfa for Acute Major Bleeding Associated with Factor Xa
Inhibitors. N Engl J Med. 2016 Sep 22;375(12):1131-41.

7: Powell J, Taylor J, Garland SG. Andexanet alfa: A Novel Factor Xa Inhibitor
Reversal Agent. Ann Pharmacother. 2019 Sep;53(9):940-946.

8: Smith MN, Deloney L, Carter C, Weant KA, Eriksson EA. Safety, efficacy, and
cost of four-factor prothrombin complex concentrate (4F-PCC) in patients with
factor Xa inhibitor-related bleeding: a retrospective study. J Thromb
Thrombolysis. 2019 Aug;48(2):250-255.

9: Kim KM, Kim J, Baek MC, Bae JS. Novel factor Xa inhibitor, maslinic acid,
with antiplatelet aggregation activity. J Cell Physiol. 2020
Dec;235(12):9445-9456.
10: Nederpelt CJ, Naar L, Sylvester KW, Barra ME, Roberts RJ, Velmahos GC,
Kaafarani HMA, Rosenthal MG, King DR. Evaluation of oral factor Xa inhibitor-
associated extracranial bleeding reversal with andexanet alfa. J Thromb Haemost.
2020 Oct;18(10):2532-2541.

Products Related to Factor Xa (Human, Highly Pure) : Proteins